The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F12%3A00060839" target="_blank" >RIV/00216224:14110/12:00060839 - isvavai.cz</a>

Alternative codes found

RIV/65269705:_____/12:#0001930

Result on the web

<a href="http://dx.doi.org/10.1038/nrclinonc.2012.150" target="_blank" >http://dx.doi.org/10.1038/nrclinonc.2012.150</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/nrclinonc.2012.150" target="_blank" >10.1038/nrclinonc.2012.150</a>

Result language

angličtina

Original language name

The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach

Original language description

Allogeneic haematopoietic stem-cell transplantation (HSCT) is frequently applied as part of the treatment in patients with acute myeloid leukaemia (AML) in their first or subsequent remission. Allogeneic HSCT reduces relapse, but nonrelapse mortality andmorbidity might counterbalance this beneficial effect. Here, we review recent studies reporting new disease-specific prognostic markers, in addition to allogeneic- HSCT-related risk factors, which can be assessed at specific time points during treatment. We propose risk assessment as a dynamic process during treatment, incorporating both disease-related and transplant-related factors for the decision to proceed either to allogeneic HSCT or to apply a nontransplant strategy. We suggest that allogeneic HSCT might be favoured if the projected disease-free survival is expected to improve by at least 10% based on an individual?s risk assessment.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2012

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Nature reviews. Clinical oncology.

ISSN

1759-4774

e-ISSN

—

Volume of the periodical

9

Issue of the periodical within the volume

10

Country of publishing house

GB - UNITED KINGDOM

Number of pages

12

Pages from-to

579-590

UT code for WoS article

000309550800010

EID of the result in the Scopus database

—